title: Lower activity of serum peptidases in abstinent alcohol-dependent patients.
abstract: This study examines i) the activity of serum prolyl endopeptidase (PEP) and dipeptidlyl peptidase IV (DPP IV) in detoxified alcohol-dependent patients without liver disease versus normal controls, and ii) the relationships between serum DPP IV and PEP activity and the production of cytokines or cytokine receptors, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), interferon-y (IFN-y), IL-1 receptor antagonist (IL-1RA), and IL-10, and granulocyte-macrophage colony stimulatory factor (GM-CSF). Alcohol-dependent patients had significantly lower serum PEP and DPP IV activity than normal controls. We found that 58.3% and 50.0% of the alcohol-dependent patients, respectively, had PEP and DPP IV activities, which were lower than the mean control values minus 2 SD. There were significant inverse correlations between lowered serum DPP IV and PEP activity and the increased production of IL-6, INF-gamma, IL-IRA, IL-10, and GM-CSF. These results show that lower serum DPP IV and PEP activity may be related to the pathophysiology of alcohol dependence.
authors.affiliation: Clinical Research Center for Mental Health, Antwerp, Belgium. m.maes@unicall.be
authors.forename: M
authors.initials: M
authors.lastname: Maes
authors.forename: A
authors.initials: A
authors.lastname: Lin
authors.forename: S
authors.initials: S
authors.lastname: Bonaccorso
authors.forename: E
authors.initials: E
authors.lastname: Vandoolaeghe
authors.forename: C
authors.initials: C
authors.lastname: Song
authors.forename: F
authors.initials: F
authors.lastname: Goossens
authors.forename: I
authors.initials: I
authors.lastname: De Meester
authors.forename: J
authors.initials: J
authors.lastname: Degroote
authors.forename: H
authors.initials: H
authors.lastname: Neels
authors.forename: S
authors.initials: S
authors.lastname: Scharpé
authors.forename: A
authors.initials: A
authors.lastname: Janca
mesh_terms: D000328:Adult; D000437:Alcoholism / Q000201:enzymology* / Q000628:therapy; D003975:Diazepam / Q000627:therapeutic use; D018819:Dipeptidyl Peptidase 4 / Q000097:blood*; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000096:biosynthesis; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D053590:Interleukin 1 Receptor Antagonist Protein; D016753:Interleukin-10 / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D008111:Liver Function Tests; D008297:Male; D000085822:Prolyl Oligopeptidases; D012697:Serine Endopeptidases / Q000097:blood*; D012795:Sialoglycoproteins / Q000096:biosynthesis; D013695:Temperance; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D015850:Interleukin-6; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D018819:Dipeptidyl Peptidase 4; D012697:Serine Endopeptidases; C000705287:PREPL protein, human; D000085822:Prolyl Oligopeptidases; D003975:Diazepam